A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorStemCyte, Inc.
About this trial
REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male or female aged ≥ 18
With post-COVID condition
Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR or antigen test)
Able to provide signed informed consent (by the subject or his/her legally authorized representative)
Disqualifiers
Neurological disorders prior to COVID-19 diagnosis
With pre-existing terminal illness
With known immune disease
Is pregnant or breastfeeding
Trial design
Design model
Parallel
Treatments tested in this trial
REGENECYTE
Biological/VaccineHPC, Cord Blood
Placebo
Biological/VaccineNormal Saline
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: REGENECYTEExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
The change of efficacy
Change of efficacy evaluation
Time frame
WeekSecondary outcomes
1
Treatment-emergent adverse events (TEAEs)
Incidence of treatment-emergent adverse events (TEAEs)
Time frame
WeekLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: